Conditions: Endometrial Cancer
Keywords: Advanced Endometrial Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 133
Healthy volunteers: no

Brief summary:
To assess the objective response rate (ORR: complete response + partial response \[CR+ PR\]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .

Detailed description:

Arms:
arm 1: Participants with advanced endometrial cancer and disease progression following platinum-based, first line chemotherapy.

Interventions: intervention 1: Lenvatinib
Intervention descriptions: intervention 1: Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.

Protocol document: